

# A Novel Engineered Peptide, a Narrow-Spectrum Antibiotic, is Effective against Vancomycin-Resistant *Enterococcus faecalis*

Xiao-Qing Qiu,<sup>1</sup> Jie Zhang,<sup>1</sup> He Wang,<sup>2</sup> and George Y. Wu<sup>3\*</sup>

Laboratory of Biomembrane and Membrane Protein, West China Hospital,<sup>1</sup> and Laboratory of Genetics,  
West China Second University Hospital,<sup>2</sup> Sichuan University, Chengdu, People's Republic of China,  
and Division of Gastroenterology-Hepatology, Department of Medicine, University of  
Connecticut Health Center, Farmington, Connecticut<sup>3</sup>

Received 2 September 2004/Returned for modification 23 October 2004/Accepted 5 November 2004

**A novel antienterococcal peptide was prepared by fusing the enterococcal cCF10 pheromone to the channel-forming domain of colicin Ia, forming *Enterococcus faecalis* pheromonin (PMC-EF). This peptide was bactericidal against vancomycin-resistant *Enterococcus faecalis* (VRE) organisms. Electron microscopy and vital dyes confirmed increased membrane permeability. All mice made bacteremic with VRE strains survived when they were treated with PMC-EF, while all controls died.**

A major problem in the treatment of bacterial infections has been the emergence of antibiotic resistance. This is true for *Enterococcus faecium* and to a lesser extent for *Enterococcus faecalis*, which have developed resistance to many antibiotics, including vancomycin (12, 16). We have shown that a staphylococcal pheromone fused to a channel-forming peptide killed staphylococci in culture and animal infections (14). Here, we report on an application of that strategy to vancomycin-resistant *E. faecalis* (VRE) strains.

*Escherichia coli* cells can secrete colicins, which possess channel-forming properties bactericidal only to *E. coli*. Colicin Ia introduces a lethal 175-residue C-terminal channel into cell membranes of targeted *E. coli* (6, 8, 10, 13, 15, 17). Our plan was to fuse the C terminus of colicin Ia to cCF10, a 7-residue pheromone produced by enterococci (2, 8). This pheromone traverses recipient cell walls and interacts with a corresponding prgZ component of the cell membrane (1, 3, 4).

**Mutagenesis of PMC-EF.** We constructed the LVTLVFV amino acid sequence of pheromone cCF10 to follow position I626 of colicin Ia by double-stranded oligonucleotide mutagenesis (QuickChange kit; Stratagene) by using a Promega pSELECT-1 plasmid containing the colicin Ia gene (P. Gosh, University of California at San Francisco) to form *E. faecalis* pheromonin (PMC-EF). We used the 5'-3' oligonucleotide containing the desired LVTLVFV mutation (in bold) GCGAATAAGTTCTGGGGTATTCTGGTTACCCTTGTGTCCGTGTAATAAAATATAAGACAGGC. Controls consisted of a random peptide of the same length as cCF10 and an unrelated staphylococcal pheromone fused at the N terminus instead of the C terminus (reversed PMC-EF) (Fig. 1a). Plasmids were transfected into TG1 *E. coli* cells and purified (7, 9).

**In vitro bactericidal assays.** We grew vancomycin-sensitive *E. faecalis* ATCC 29212 and vancomycin-resistant *E. faecalis* ATCC 700802 (American Type Culture Collection, Manassas, Va.) as described previously (3). Shenyang Biotechnic Co. (Shanghai, People's Republic of China) synthesized cCF10.

Wild-type colicin Ia from TG1 cells transfected with colicin Ia plasmid, PMC-EF from TG1 cells transfected with reversed PMC-EF, a random protein with an SMTTVGG peptide introduced at the C terminus of colicin Ia, penicillin, and vancomycin served as controls. Turbidimetric measurements and colony counting were performed (5).

**Electron microscopy and immunolabeling.** We incubated VRE cells with PMC-EF, vancomycin, or growth medium alone for 2 h, then stained them with 1% phosphotungstic acid, and observed them under an electron microscope (Jeol JEM-100SX; Jeol, Akishima, Japan) at a magnification of  $\times 15,000$  to  $\times 40,000$ .

We incubated VRE and BAA-42 methicillin-resistant *Staphylococcus aureus* cells with PMC-EF, PMC-EF plus free cCF10, vancomycin, or growth medium alone for 40 min, then fixed the cells in phosphate-buffered saline-paraformaldehyde, incubated specimens with rabbit anti-colicin Ia antibody (1:10 in 3% skim milk) (Babco Berkeley Antibody Co., Richmond, Calif.) followed by goat anti-rabbit antibody labeled with 5-nm-diameter gold particles (1:100 in 3% skim milk) (Wuhan Boster Biol. Tech. Co., Wuhan, People's Republic of China), and fixed the cells in phosphate-buffered saline-glutaraldehyde. Specimens were fixed in OsO<sub>4</sub> and embedded in Epon 812. Ultrathin sections were stained with uranyl acetate and lead citrate and then observed with a Hitachi H-600 electron microscope at 80 kV (11).

The domains of the fusion peptide PMC-EF are shown in Fig. 1a and b. Figure 1c shows a polyacrylamide gel of the enterococcal chimeric protein PMC-EF (Fig. 1c, lane 2) and a control chimeric protein containing pheromone from *S. aureus* (PMC-SA) (Fig. 1c, lane 3).

Exposure of *E. faecalis* ATCC 29212 nonresistant cells to PMC-EF inhibited growth by 90% (Fig. 2a), while penicillin G

\* Corresponding author. Mailing address: Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Rm. AM-044, 263 Farmington Ave., Farmington, CT 06030-1845. Phone: (860) 679-3158. Fax: (860) 679-3159. E-mail: wu@nso.uhc.edu.




FIG. 1. Structure of PMC-EF. (a, upper panel) Shown is an 8.3-kbp colicin Ia plasmid used for site-directed mutagenesis and subsequent preparation of PMC-EF consisting of the colicin Ia plasmid with insertion of a cCF10 (EF) pheromone gene, PMC-SA with insertion of an unrelated staphylococcal pheromone (YSTCDFIM), or insertion of a random (SMTTVGG) peptide gene following amino acid position I626. (a, lower panel) Shown is a construct with insertion of cCF10 before amino acid position S1 of colicin Ia to form the reversed PMC-EF control. (b) Domain diagram of the PMC-EF construct with the cCF10 pheromone at the C terminus and the reversed PMC-EF construct with cCF10 pheromone at the N terminus. (c) Sodium dodecyl sulfate-15% polyacrylamide gel of PMC-EF purified by gradient elution from a carboxymethyl column: lane 1, molecular weight markers; lane 2, PMC-EF; and lane 3, PMC-SA.

inhibited growth by 80%. Control peptides with an unrelated 8-residue staphylococcal pheromone or a random 7-residue peptide linked at the C terminus of colicin Ia had no effects. Vancomycin (5  $\mu$ g/ml) slowed initial growth of VRE cells (Fig. 2b). However, later there was no significant difference compared to untreated controls. In contrast, 5  $\mu$ g of PMC-EF/ml inhibited VRE cell growth by 85%. Addition of free cCF10 pheromone (Fig. 2c) blocked PMC-EF inhibition of VRE cell growth in a concentration-dependent manner. Incubation of VRE with either free cCF10 or wild-type colicin Ia alone (Fig. 2d) did not inhibit cell growth. In contrast, PMC-EF resulted in less than 10% growth inhibition when administered to *S. aureus* or *Streptococcus pneumoniae* (Fig. 2e and f). Exposure of *S. aureus* cells to PMC-SA, a control chimeric protein containing pheromone from *S. aureus*, caused an 80% growth inhibition (Fig. 2e) (14). Withdrawal of PMC-EF failed to restore growth (data not shown).

Electron microscopy of VRE cells incubated with vancomycin (Fig. 3b) showed a morphological appearance like that of untreated cells (Fig. 3a). In contrast, after incubation with

PMC-EF, 60% of VRE cells per field were distorted (Fig. 3c and d) (less than 7% per field were distorted in controls). Free cCF10 blocked adsorption of gold-labeled antibody on cytoplasmic membranes of enterococcal cells treated with PMC-EF (Fig. 3h). As shown in Fig. 3f and g, some VRE cells exposed to PMC-EF developed ruptured cell walls.

Initially after exposure to PMC-EF (Fig. 4a), the number of VRE cells stained (green) by fluorescein isothiocyanate (FITC)-labeled antibody exceeded that stained (red) with propidium iodide, a vital dye. The ratio of red to green VRE cells increased with time (Fig. 4a to d). The number of dual-labeled cells increased to a maximum at 0.5 h (Fig. 4b) and then declined, while cells with propidium iodide staining decreased, and FITC staining was almost absent by 2 h (Fig. 4d). There was no significant propidium staining and no FITC labeling of untreated cells (Fig. 4e to h).

In a mouse VRE sepsis model, all mice treated with PMC-EF survived, while all untreated mice died within 3 days. None of the *E. faecalis*-infected mice survived with vancomycin (data not shown).




FIG. 2. Measurement of bactericidal activity of PMC-EF against *E. faecalis* by in vitro cell growth assays. The following additions were made to the media: no addition (Control), penicillin G (PEN), vancomycin (VAN), wild-type colicin Ia (COL), free cCF10 pheromone alone (cCF10), staphylococcal colicin fusion protein (PMC-SA), colicin Ia with C-terminal random 7-residue peptide (RANDOM), and enterococcal colicin fusion protein (PMC-EF). *E. faecalis* 29212, a vancomycin-sensitive *E. faecalis* strain, was incubated with all additives at 2 µg/ml (a) or all additives at 5 µg/ml (b). (c) Free cCF10 pheromone (1 µg/ml) was added to compete with increasing concentrations of PMC-EF against ATCC 700802 *E. faecalis* cells. (d) Growth of ATCC 700802 VRE cells treated with 1 µg of free cCF10/ml or 10 µg of wild-type colicin Ia or PMC-EF/ml. (e) Growth of *S. aureus* ATCC BAA-42 with 4 µg of PMC-EF or PMC-SA (an unrelated staphylococcal chimeric protein)/ml. (f) Growth of *S. pneumoniae* 31201 with 1 µg of PMC-EF or penicillin G/ml.




FIG. 3. Electron micrographs of ATCC 700802 VRE cells. (a) Untreated cells. (b) Vancomycin-treated cells (5  $\mu\text{g/ml}$ ). (c and d) PMC-EF-treated cells (5  $\mu\text{g/ml}$ ). (a to d) Negative staining. Magnification,  $\times 15,000$ . Cells were incubated and stained with rabbit anticolicin antibody and gold-labeled goat anti-rabbit antibody. (e to g) VRE cells were treated with PMC-EF (20  $\mu\text{g/ml}$ ). (h) Cells treated with PMC-EF (20  $\mu\text{g/ml}$ ) and competed with free cCF10 (1  $\mu\text{g/ml}$ ). Magnification,  $\times 30,000$  to  $\times 40,000$ . Insets show full-field views.




FIG. 4. Cells treated with PMC-EF (a to d) or medium alone (e to h) stained with propidium iodide and FITC-labeled antibody and examined under a confocal microscope. The following times elapsed after additions: 0.1 h, panels a and e; 0.5 h, panels b and f; 1 h, panels c and g; and 2 h, panels d and h. Insets show full-field views.

The emergence of vancomycin-resistant enterococci has been the result of increased use of vancomycin in enterococcal infections (12, 16). In addition, conjugal transfer of the *vanA* operon from enterococci has resulted in vancomycin resistance in other bacteria (12, 16). Multidrug resistance is now common among those pathogens (12, 16). Successful treatment of antibiotic-resistant bacteria will require novel agents whose mechanisms of action are different from those of conventional agents.

We conclude that a chimeric peptide containing pheromone and channel-forming domains can be targeted to antibiotic-

resistant bacteria, resulting in substantial bactericidal effects. Furthermore, because a variety of pheromones are known, fusion peptides could be tailored to particular bacteria and provide novel "narrow-spectrum" antibiotics.

This work was supported by National Nature Science Foundation of China grants 39725009, 39770243, and 30276820 and National Basic Research Program of China grant G19990540001 to X.-Q.Q.; a grant from the National Institute of Diabetes and Digestive and Kidney Disorders (DK-42182) to G.Y.W.; and the Herman Lopata Chair in Hepatitis Research to G.Y.W.

## REFERENCES

1. **Buttaro, B. A., M. H. Antiporta, and G. M. Dunny.** 2000. Cell-associated pheromone peptide (cCF10) production and pheromone inhibition in *Enterococcus faecalis*. *J. Bacteriol.* **182**:4926–4933.
2. **Dunny, G. M., and B. A. B. Leonard.** 1997. Cell-cell communication in gram-positive bacteria. *Annu. Rev. Microbiol.* **51**:527–564.
3. **Haas, W., B. Shepard, and M. Gilmore.** 2002. Two-component regulator of *Enterococcus faecalis* cytolysin responds to quorum-sensing autoinduction. *Nature* **415**:84–87.
4. **Hancock, L., and M. Perego.** 2002. Two-component signal transduction in *Enterococcus faecalis*. *J. Bacteriol.* **184**:5819–5825.
5. **Harlow, E., and D. Lane.** 1999. Using antibodies: a laboratory manual, p. 71. Cold Spring Harbor Laboratory Press, Woodbury, N.Y.
6. **Jacob, F., L. Siminovitch, and E. Wollman.** 1952. Sur la biosynthèse d'une colicine et sur son mode d'action. *Ann. Inst. Pasteur* **83**:295–315.
7. **Jakes, K. S., C. K. Abrams, and A. Finkelstein.** 1990. Alteration of the pH-dependent ion selectivity of the colicin E1 channel by site-directed mutagenesis. *J. Biol. Chem.* **265**:6984–6991.
8. **Kienker, P. K., X. Q. Qiu, S. L. Slatin, and A. Finkelstein.** 1997. Transmembrane insertion of the colicin Ia hydrophobic hairpin. *J. Membr. Biol.* **157**:27–37.
9. **Madigan, M. T., J. M. Martinko, and J. Parker.** 1997. Brock biology of microorganisms, 8th ed., p. 151–179. Prentice Hall, Inc., London, United Kingdom.
10. **Mankovich, J. A., C. H. Hsu, and J. Konisky.** 1986. DNA and amino acid sequence analysis of structural and immunity genes of colicins Ia and Ib. *J. Bacteriol.* **168**:228–236.
11. **Mongodin, E., O. Bajolet, and J. Hinnrasky.** 2000. Cell wall-associated protein A as a tool for immunolocalization of *Staphylococcus aureus* in infected human airway epithelium. *J. Histochem. Cytochem.* **48**:523–533.
12. **Paulsen, I. T., L. Banerjee, and G. S. Myers.** 2003. Role of mobile DNA in the evolution of vancomycin-resistant *Enterococcus faecalis*. *Science* **299**:2071–2074.
13. **Qiu, X. Q., K. S. Jakes, and P. K. Kienker.** 1996. Major transmembrane movement associated with colicin Ia channel gating. *J. Gen. Physiol.* **107**:313–328.
14. **Qiu, X. Q., H. Wang, and X. F. Lu.** 2003. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. *Nat. Biotechnol.* **21**:1480–1485.
15. **Schein, S. J., B. L. Kagan, and A. Finkelstein.** 1978. Colicin K acts by forming voltage-dependent channels in phospholipid bilayer membranes. *Nature* **276**:159–163.
16. **Shankar, N., A. Baghdayan, and M. Gilmore.** 2002. Modulation of virulence within a pathogenicity island in vancomycin-resistant *Enterococcus faecalis*. *Nature* **417**:746–750.
17. **Slatin, S. L., X. Q. Qiu, and K. S. Jakes.** 1994. Identification of a translocated protein segment in a voltage-dependent channel. *Nature* **371**:158–161.